Ovid Therapeutics Strengthens Leadership with Four Appointments and 2029 Cash Runway
OVID•Ovid Therapeutics appointed Kevin Norrett as Chief Business Officer, promoted Charles Carter to CFO and Victoria Fort to Chief Strategy Officer, and hired Eliseo Salinas as Executive R&D Advisor to bolster corporate and research leadership. Fort’s financing efforts have extended the company’s cash runway into 2029 while Salinas brings experience from 15 regulatory approvals.
1. Executive Leadership Changes
Kevin Norrett joins as Chief Business Officer with over 30 years in life sciences, including leading Soleno Therapeutics’ acquisition by Neurocrine, and will spearhead strategic partnerships and corporate development. Charles Carter is promoted to Chief Financial Officer after overseeing Ovid’s financial planning and operations, while Victoria Fort becomes Chief Strategy Officer following her role in investor relations and corporate affairs.
2. Financial Strategy and Runway Extension
Under Fort’s leadership, Ovid completed two financing rounds that extended its cash runway into 2029, positioning the company to fund ongoing and future clinical studies. Carter’s elevation to CFO ensures continuity in financial oversight as Ovid advances late-stage programs and explores value-creating transactions.
3. R&D Guidance and Pipeline Advancement
Eliseo Salinas, MD, transitions from consultant to Executive R&D Advisor, bringing three decades of drug development expertise and a track record of 15 international regulatory approvals. His guidance will focus on advancing Ovid’s next-generation GABA-aminotransferase inhibitor OV329 and KCC2 activator series through clinical characterization.
